Elicio Therapeutics

Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.